Rotavirus 2/6 Viruslike Particles Administered Intranasally with Cholera Toxin, Escherichia coli Heat-Labile Toxin (LT), and LT-R192G Induce Protection from Rotavirus Challenge

Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue Spotlights in the Current Issue JVI About JVI Subscribers Authors Reviewers Advertisers Inquiries from...

Full description

Saved in:
Bibliographic Details
Published inJournal of Virology Vol. 72; no. 4; pp. 3390 - 3393
Main Authors O'Neal, C M, Clements, J D, Estes, M K, Conner, M E
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 01.04.1998
SeriesNote
Subjects
Administration, Intranasal
Animals
Antigens, Viral
Bacterial Toxins - immunology
Capsid - immunology
Capsid Proteins
Cholera Toxin - immunology
Disease Models, Animal
Enterotoxins - immunology
Escherichia coli
Escherichia coli Proteins
Female
Humans
Mice
Nasal Mucosa
Rotavirus - immunology
Rotavirus Infections - prevention & control
Vaccines, Synthetic - administration & dosage
Vaccines, Synthetic - immunology
Viral Pathogenesis and Immunity
Viral Vaccines - administration & dosage
Viral Vaccines - immunology
Virion
Online AccessGet full text

Cover

Abstract Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue Spotlights in the Current Issue JVI About JVI Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy JVI RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0022-538X Online ISSN: 1098-5514 Copyright © 2014 by the American Society for Microbiology.   For an alternate route to JVI .asm.org, visit: JVI       
AbstractList We have shown that rotavirus 2/6 viruslike particles composed of proteins VP2 and VP6 (2/6-VLPs) administered to mice intranasally with cholera toxin (CT) induced protection from rotavirus challenge, as measured by virus shedding. Since it is unclear if CT will be approved for human use, we evaluated the adjuvanticity of Escherichia coli heat-labile toxin (LT) and LT-R192G. Mice were inoculated intranasally with 10 μg of 2/6-VLPs combined with CT, LT, or LT-R192G. All three adjuvants induced equivalent geometric mean titers of rotavirus-specific serum antibody and intestinal immunoglobulin G (IgG). Mice inoculated with 2/6-VLPs with LT produced significantly higher titers of intestinal IgA than mice given CT as the adjuvant. All mice inoculated with 2/6-VLPs mixed with LT and LT-R192G were totally protected (100%) from rotavirus challenge, while mice inoculated with 2/6-VLPs mixed with CT showed a mean 91% protection from challenge. The availability of a safe, effective mucosal adjuvant such as LT-R192G will increase the practicality of administering recombinant vaccines mucosally.
We have shown that rotavirus 2/6 viruslike particles composed of proteins VP2 and VP6 (2/6-VLPs) administered to mice intranasally with cholera toxin (CT) induced protection from rotavirus challenge, as measured by virus shedding. Since it is unclear if CT will be approved for human use, we evaluated the adjuvanticity of Escherichia coli heat-labile toxin (LT) and LT-R192G. Mice were inoculated intranasally with 10 mu g of 2/6-VLPs combined with CT, LT, or LT-R192G. All three adjuvants induced equivalent geometric mean titers of rotavirus-specific serum antibody and intestinal immunoglobulin G (IgG). Mice inoculated with 2/6-VLPs with LT produced significantly higher titers of intestinal IgA than mice given CT as the adjuvant. All mice inoculated with 2/6-VLPs mixed with LT and LT-R192G were totally protected (100%) from rotavirus challenge, while mice inoculated with 2/6-VLPs mixed with CT showed a mean 91% protection from challenge. The availability of a safe, effective mucosal adjuvant such as LT-R192G will increase the practicality of administering recombinant vaccines mucosally.
We have shown that rotavirus 2/6 viruslike particles composed of proteins VP2 and VP6 (2/6-VLPs) administered to mice intranasally with cholera toxin (CT) induced protection from rotavirus challenge, as measured by virus shedding. Since it is unclear if CT will be approved for human use, we evaluated the adjuvanticity of Escherichia coli heat-labile toxin (LT) and LT-R192G. Mice were inoculated intranasally with 10 microg of 2/6-VLPs combined with CT, LT, or LT-R192G. All three adjuvants induced equivalent geometric mean titers of rotavirus-specific serum antibody and intestinal immunoglobulin G (IgG). Mice inoculated with 2/6-VLPs with LT produced significantly higher titers of intestinal IgA than mice given CT as the adjuvant. All mice inoculated with 2/6-VLPs mixed with LT and LT-R192G were totally protected (100%) from rotavirus challenge, while mice inoculated with 2/6-VLPs mixed with CT showed a mean 91% protection from challenge. The availability of a safe, effective mucosal adjuvant such as LT-R192G will increase the practicality of administering recombinant vaccines mucosally.
Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue Spotlights in the Current Issue JVI About JVI Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy JVI RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0022-538X Online ISSN: 1098-5514 Copyright © 2014 by the American Society for Microbiology.   For an alternate route to JVI .asm.org, visit: JVI       
ABSTRACT We have shown that rotavirus 2/6 viruslike particles composed of proteins VP2 and VP6 (2/6-VLPs) administered to mice intranasally with cholera toxin (CT) induced protection from rotavirus challenge, as measured by virus shedding. Since it is unclear if CT will be approved for human use, we evaluated the adjuvanticity of Escherichia coli heat-labile toxin (LT) and LT-R192G. Mice were inoculated intranasally with 10 μg of 2/6-VLPs combined with CT, LT, or LT-R192G. All three adjuvants induced equivalent geometric mean titers of rotavirus-specific serum antibody and intestinal immunoglobulin G (IgG). Mice inoculated with 2/6-VLPs with LT produced significantly higher titers of intestinal IgA than mice given CT as the adjuvant. All mice inoculated with 2/6-VLPs mixed with LT and LT-R192G were totally protected (100%) from rotavirus challenge, while mice inoculated with 2/6-VLPs mixed with CT showed a mean 91% protection from challenge. The availability of a safe, effective mucosal adjuvant such as LT-R192G will increase the practicality of administering recombinant vaccines mucosally.
Author Christine M. O’Neal
John D. Clements
Mary K. Estes
Margaret E. Conner
AuthorAffiliation Division of Molecular Virology, Baylor College of Medicine, Houston, Texas 77030, 1 and Department of Microbiology and Immunology, Tulane University Medical Center, New Orleans, Louisiana 70112 2
AuthorAffiliation_xml – name: Division of Molecular Virology, Baylor College of Medicine, Houston, Texas 77030, 1 and Department of Microbiology and Immunology, Tulane University Medical Center, New Orleans, Louisiana 70112 2
Author_xml – sequence: 1
  givenname: C M
  surname: O'Neal
  fullname: O'Neal, C M
  organization: Division of Molecular Virology, Baylor College of Medicine, Houston, Texas 77030, USA
– sequence: 2
  givenname: J D
  surname: Clements
  fullname: Clements, J D
– sequence: 3
  givenname: M K
  surname: Estes
  fullname: Estes, M K
– sequence: 4
  givenname: M E
  surname: Conner
  fullname: Conner, M E
BackLink https://www.ncbi.nlm.nih.gov/pubmed/9525668$$D View this record in MEDLINE/PubMed
BookMark eNpVUs1u1DAQtlBRaQuPgDAXBFKzjR07cQ4cqlVpF60EqpaKm-U4k42LY7d2dkvfikfE0a5auIwtzXw_ns_H6MB5Bwi9I_mMECrObrdmVtEZmxVFnWepFDNS1-IFOiJ5LTLOCTtAR3lOacYL8fMVOo7xNs8JYyU7RIc1p7wsxRH6c-1HtTVhEzE9K_HNdLPmF-DvKoxGW4j4vB2MM3GEAC1euDEop6Ky9hE_mLHH895bCAqv_G_jTvFF1D0Eo3ujsPbW4CtQY7ZUjbGwm8Efl6tPp1i5Fi9X2TWp6WWibTc6iQY_gh6Nd7gLfsDP5uZ9UgS3htfoZadshDf78wT9-HKxml9ly2-Xi_n5MtOsFGPWiZrUvC4Jh65pQTSCNEyUHWgNgnJedqJttO66tC5WVYx3vMo7VlNSFKIteHGCPu947zbNAK2G6eFW3gUzqPAovTLy_44zvVz7rZz2T-uE_7DHB3-_gTjKwUQN1ioHfhMlKWmVbNA0WO0GdfAxBuieNEgup6zl15uFrKhkcsp6KoWcsk7It_9afMLtw03997t-b9b9gwkgVRxk-jnPbMVftjK2Gw
CitedBy_id crossref_primary_10_1016_S0042_6822_03_00027_8
crossref_primary_10_1128_JVI_75_22_11010_11016_2001
crossref_primary_10_1016_S0264_410X_03_00308_6
crossref_primary_10_1128_JVI_75_20_9713_9722_2001
crossref_primary_10_1016_S0165_2427_99_00074_4
crossref_primary_10_1016_j_vaccine_2013_02_019
crossref_primary_10_1016_j_vaccine_2009_03_043
crossref_primary_10_1016_j_vaccine_2006_12_001
crossref_primary_10_1128_IAI_73_8_5256_5261_2005
crossref_primary_10_1128_IAI_67_2_826_833_1999
crossref_primary_10_1002__SICI_1096_9071_199911_59_3_369__AID_JMV18_3_0_CO_2_N
crossref_primary_10_1016_j_vaccine_2017_03_104
crossref_primary_10_1099_0022_1317_81_5_1237
crossref_primary_10_1016_j_vaccine_2004_11_072
crossref_primary_10_1016_j_vaccine_2008_05_089
crossref_primary_10_1016_S0264_410X_99_00447_8
crossref_primary_10_1016_j_vetimm_2010_04_015
crossref_primary_10_1078_1438_4221_00241
crossref_primary_10_1007_s11427_010_4104_3
crossref_primary_10_1016_j_vaccine_2004_06_018
crossref_primary_10_1021_mp300597g
crossref_primary_10_1128_JVI_02052_06
crossref_primary_10_1016_j_fsi_2020_07_016
crossref_primary_10_1016_S0264_410X_00_00543_0
crossref_primary_10_1089_vim_2009_0017
crossref_primary_10_1016_j_vaccine_2004_10_025
crossref_primary_10_1128_JVI_75_19_9229_9238_2001
crossref_primary_10_4049_jimmunol_165_11_6454
crossref_primary_10_1002_jmv_23973
crossref_primary_10_1128_JVI_80_4_1752_1761_2006
crossref_primary_10_1128_JVI_01727_07
crossref_primary_10_1016_j_vaccine_2012_10_083
crossref_primary_10_1586_erv_13_3
crossref_primary_10_1128_JVI_72_11_9233_9246_1998
crossref_primary_10_1016_j_vaccine_2007_01_107
crossref_primary_10_1128_CDLI_11_1_12_20_2004
crossref_primary_10_1016_S0264_410X_02_00617_5
crossref_primary_10_1016_S0264_410X_00_00058_X
crossref_primary_10_1016_j_virusres_2009_04_005
crossref_primary_10_1016_j_micpath_2014_02_005
crossref_primary_10_1016_S0966_842X_99_01682_0
crossref_primary_10_1097_00006454_200101000_00004
crossref_primary_10_1016_S0264_410X_99_00168_1
crossref_primary_10_1016_S0165_2427_02_00046_6
crossref_primary_10_1128_JVI_73_9_7574_7581_1999
crossref_primary_10_1089_08828240151061365
crossref_primary_10_1128_JVI_80_8_3823_3832_2006
crossref_primary_10_1016_j_virol_2005_11_016
crossref_primary_10_3390_toxins2082007
crossref_primary_10_1097_01_inf_0000197707_70835_f3
crossref_primary_10_1128_JVI_74_19_8843_8853_2000
crossref_primary_10_2165_00063030_200014050_00001
crossref_primary_10_1016_j_vaccine_2007_05_065
crossref_primary_10_1016_S0264_410X_02_00031_2
crossref_primary_10_1016_j_vaccine_2004_11_010
crossref_primary_10_1128_JVI_75_10_4752_4760_2001
crossref_primary_10_3390_v8040115
crossref_primary_10_1016_S0264_410X_01_00452_2
crossref_primary_10_1097_00001574_200101000_00003
crossref_primary_10_1128_JVI_80_10_4949_4961_2006
crossref_primary_10_1097_00001574_199901000_00010
crossref_primary_10_1111_j_1365_2567_2007_02676_x
crossref_primary_10_1002__SICI_1097_0290_19981105_60_3_369__AID_BIT14_3_0_CO_2_H
crossref_primary_10_1128_JVI_73_9_7565_7573_1999
crossref_primary_10_1080_mmy_40_3_291_299
crossref_primary_10_1128_JVI_00844_10
crossref_primary_10_1016_j_vaccine_2005_03_009
crossref_primary_10_1016_j_vaccine_2007_01_087
crossref_primary_10_1189_jlb_0307173
crossref_primary_10_1002_eji_200526059
crossref_primary_10_1016_S0264_410X_98_00317_X
crossref_primary_10_1128_CVI_00395_09
crossref_primary_10_1002_jmv_10178
crossref_primary_10_1128_IAI_67_4_1694_1701_1999
crossref_primary_10_1006_viro_2001_1180
crossref_primary_10_1586_erv_12_31
crossref_primary_10_1016_S0264_410X_02_00516_9
crossref_primary_10_1385_MB_27_1_59
crossref_primary_10_1051_vetres_2006014
crossref_primary_10_1016_S0197_4580_02_00127_6
Cites_doi 10.1016/0264-410X(88)90223-X
10.1128/jvi.68.9.5945-5952.1994
10.1128/jvi.71.11.8707-8717.1997
10.1128/iai.65.1.331-334.1997
10.1128/iai.59.9.2870-2879.1991
10.1016/B978-012410580-5/50006-6
10.1128/iai.24.3.760-769.1979
10.1128/jvi.68.12.7766-7773.1994
10.1084/jem.185.7.1203
10.1073/pnas.92.5.1644
10.2165/00128413-199711100-00016
10.1128/iai.63.5.1617-1623.1995
10.1128/jvi.69.12.7800-7806.1995
10.1128/mr.47.4.510-550.1983
ContentType Journal Article
Copyright Copyright © 1998, American Society for Microbiology 1998
Copyright_xml – notice: Copyright © 1998, American Society for Microbiology 1998
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7T5
7T7
7U9
8FD
C1K
FR3
H94
P64
5PM
DOI 10.1128/jvi.72.4.3390-3393.1998
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Immunology Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
Biotechnology and BioEngineering Abstracts
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Virology and AIDS Abstracts
Technology Research Database
AIDS and Cancer Research Abstracts
Immunology Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
DatabaseTitleList
Virology and AIDS Abstracts
MEDLINE

CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1098-5514
EndPage 3393
ExternalDocumentID 10_1128_JVI_72_4_3390_3393_1998
9525668
jvi_72_4_3390
Genre Journal Article
GroupedDBID ---
-~X
.55
.GJ
0R~
18M
29L
2WC
39C
3O-
4.4
41~
53G
5GY
5RE
5VS
6TJ
85S
AAYJJ
ABPPZ
ACGFO
ACNCT
ADBBV
AENEX
AFFNX
AGVNZ
AI.
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
C1A
CGR
CS3
CUY
CVF
D0S
DIK
E3Z
EBS
ECM
EIF
EJD
F20
F5P
FRP
GX1
H13
HYE
HZ~
IH2
KQ8
MVM
N9A
NPM
O9-
OHT
OK1
P2P
RHF
RHI
RNS
RPM
RSF
TR2
UCJ
UPT
VH1
W2D
W8F
WH7
WOQ
X7M
Y6R
YQT
ZGI
ZXP
~02
~KM
AAYXX
CITATION
7T5
7T7
7U9
8FD
C1K
FR3
H94
P64
5PM
ID FETCH-LOGICAL-c468t-f891959615efbde8b81b486fecce82556f8dbccff10947745f570f4921338d353
IEDL.DBID RPM
ISSN 0022-538X
IngestDate Tue Sep 17 21:26:43 EDT 2024
Fri Oct 25 03:57:54 EDT 2024
Thu Sep 12 17:17:06 EDT 2024
Sat Sep 28 08:26:51 EDT 2024
Wed May 18 15:25:45 EDT 2016
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c468t-f891959615efbde8b81b486fecce82556f8dbccff10947745f570f4921338d353
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Corresponding author. Mailing address: Rm. 936E, Division of Molecular Virology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. Phone: (713) 798-3590. Fax: (713) 798-3586. E-mail: mconner@bcm.tmc.edu.
OpenAccessLink https://jvi.asm.org/content/jvi/72/4/3390.full.pdf
PMID 9525668
PQID 16275562
PQPubID 23462
PageCount 4
ParticipantIDs proquest_miscellaneous_16275562
pubmed_primary_9525668
highwire_asm_jvi_72_4_3390
pubmedcentral_primary_oai_pubmedcentral_nih_gov_109829
crossref_primary_10_1128_JVI_72_4_3390_3393_1998
PublicationCentury 1900
PublicationDate 1998-04-01
PublicationDateYYYYMMDD 1998-04-01
PublicationDate_xml – month: 04
  year: 1998
  text: 1998-04-01
  day: 01
PublicationDecade 1990
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationSeriesTitle Note
PublicationTitle Journal of Virology
PublicationTitleAlternate J Virol
PublicationYear 1998
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_2_9_2
e_1_3_2_15_2
e_1_3_2_8_2
e_1_3_2_16_2
e_1_3_2_7_2
Institute of Medicine (e_1_3_2_11_2) 1986; 2
Katz J. M. (e_1_3_2_12_2) 1996; 3
e_1_3_2_17_2
e_1_3_2_6_2
e_1_3_2_10_2
e_1_3_2_5_2
e_1_3_2_4_2
e_1_3_2_3_2
e_1_3_2_13_2
e_1_3_2_2_2
e_1_3_2_14_2
References_xml – ident: e_1_3_2_3_2
  doi: 10.1016/0264-410X(88)90223-X
– ident: e_1_3_2_4_2
  doi: 10.1128/jvi.68.9.5945-5952.1994
– ident: e_1_3_2_15_2
  doi: 10.1128/jvi.71.11.8707-8717.1997
– ident: e_1_3_2_10_2
  doi: 10.1128/iai.65.1.331-334.1997
– volume: 3
  start-page: 292
  year: 1996
  ident: e_1_3_2_12_2
  article-title: Heat labile enterotoxin from Escherichia coli as an adjuvant for oral influenza vaccination
  publication-title: Options for the control of influenza
  contributor:
    fullname: Katz J. M.
– ident: e_1_3_2_14_2
  doi: 10.1128/iai.59.9.2870-2879.1991
– ident: e_1_3_2_6_2
  doi: 10.1016/B978-012410580-5/50006-6
– ident: e_1_3_2_2_2
  doi: 10.1128/iai.24.3.760-769.1979
– ident: e_1_3_2_8_2
  doi: 10.1128/jvi.68.12.7766-7773.1994
– ident: e_1_3_2_17_2
  doi: 10.1084/jem.185.7.1203
– volume: 2
  start-page: 308
  year: 1986
  ident: e_1_3_2_11_2
  article-title: New vaccine development. Establishing priorities
  publication-title: Diseases of importance in developing countries
  contributor:
    fullname: Institute of Medicine
– ident: e_1_3_2_7_2
  doi: 10.1073/pnas.92.5.1644
– ident: e_1_3_2_16_2
  doi: 10.2165/00128413-199711100-00016
– ident: e_1_3_2_5_2
  doi: 10.1128/iai.63.5.1617-1623.1995
– ident: e_1_3_2_9_2
  doi: 10.1128/jvi.69.12.7800-7806.1995
– ident: e_1_3_2_13_2
  doi: 10.1128/mr.47.4.510-550.1983
SSID ssj0014464
Score 1.961451
Snippet Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley...
We have shown that rotavirus 2/6 viruslike particles composed of proteins VP2 and VP6 (2/6-VLPs) administered to mice intranasally with cholera toxin (CT)...
ABSTRACT We have shown that rotavirus 2/6 viruslike particles composed of proteins VP2 and VP6 (2/6-VLPs) administered to mice intranasally with cholera toxin...
SourceID pubmedcentral
proquest
crossref
pubmed
highwire
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 3390
SubjectTerms Administration, Intranasal
Animals
Antigens, Viral
Bacterial Toxins - immunology
Capsid - immunology
Capsid Proteins
Cholera Toxin - immunology
Disease Models, Animal
Enterotoxins - immunology
Escherichia coli
Escherichia coli Proteins
Female
Humans
Mice
Nasal Mucosa
Rotavirus - immunology
Rotavirus Infections - prevention & control
Vaccines, Synthetic - administration & dosage
Vaccines, Synthetic - immunology
Viral Pathogenesis and Immunity
Viral Vaccines - administration & dosage
Viral Vaccines - immunology
Virion
Title Rotavirus 2/6 Viruslike Particles Administered Intranasally with Cholera Toxin, Escherichia coli Heat-Labile Toxin (LT), and LT-R192G Induce Protection from Rotavirus Challenge
URI http://jvi.asm.org/content/72/4/3390.abstract
https://www.ncbi.nlm.nih.gov/pubmed/9525668
https://search.proquest.com/docview/16275562
https://pubmed.ncbi.nlm.nih.gov/PMC109829
Volume 72
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBbdQCCX0leo0ybVoYcW4pcs2_KxLEk2YVNC2IS9CdmSqNtdbVjvhuRf9Sd2Zm3nUXrqRRgsI5tvJH1jzXxDyGcWpdpU3Pg20crnotC-0haDHOMy1tzwJMLk5PPv2eiKn03TaZcU1nRhla4q68DN5oGrf2xiK2_mVdjHiYUX58M4KgQrwgEZgH32Hnp3cgDuDe8VwmEyT7uYLliGw5-3dZCzgAcJOPo-NAnm6okdsl2ksPOj2urTvanXC_4X9_w7hPLJnnT8irzsyCT91r70a_LCuDdkuy0vef-W_L5crNRtvVw3lIUZvcarWf3L0Iv-M2mvnYsVO-kpDuJUo2aze4o_aOkQq-cuFZ0s7mp3SI8ahLjG8GgKBlTTEazk_hhFek3bh34ZT74eUuU0HU_8SyB2JxSrg1QwaKsIAXZAMaeFPr7csC_o8o5cHR9NhiO_q9DgVzwTK9-KAsVpgBUZW2ojSiDBXGQW7MIIFDezQpdVZS0gxoFopjbNI8sLhp6xTtJkl2y5hTPvCS1iZpMcCF-pSx6rTIB7K1SeAOMzjGnukajHRt60Qhxy48AwIc-uT2XOJJcILDaJRGA9stdjKFUzl4D_YzePfOpRlTCj8JhEObNYNzJG4WaghR7ZbTF-GK8zE49kz8B_uI9S3c_vgAVvJLtbi9373wc_kJ02FxIjhj6SrdVybfaBDK3KAzI4mcYHmznwB2MnChE
link.rule.ids 230,315,730,783,787,888,27937,27938,53805,53807
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb5swFLa2TtX6sns12m31wx42qRAuBszjFLVLuqSqqqTKm2WwrbImpApJtfZX7SfunIB70162F4RkLgY-4-_Ad75DyOfQj5UumHZNpKTLeKZcqQyKHIM8UEyzyMfk5OFx0huzo0k8aZPC6lZWWRV56VXTmVeV52tt5eWs6FidWOdk2A38jIdZ5yl5BsPVj22M3v47gACHWY9waJ-0qi54EXd-XpVeGnrMiyDUd2ERYbYe3yKbWQxzP_qt3p-drGPw39jnYxHlvVnp8CUZ2-tpxCgX3mqZe8XNI6vHf73gV-RFS1Ppt6b1NXmiqzdksylcef2W_D6dL-VVuVjVNOwk9AzXpuWFpif2eNS68mItUNrHzleyltPpNcVPv7SLdXkXko7mv8pqnx7UCJ4ShdcUoFnSHswR7gDtf3WzDf0yGH3dp7JSdDByT4EyfqdYd6SAkzZeE4Awitky9K5zXVsq5h0ZHx6Muj23rf3gFizhS9fwDG1vgG9pkyvNc6DXjCcGEKc52qYZrvKiMAZuDQMKG5s49Q3LQoy5VRRH22Sjmlf6PaFZEJooBSqZq5wFMuEQOHOZRsAldRgq5hDfPnNx2Vh8iHVoFHJxdNYXaSiYQMDgIhIIGIfsWGwIWc8E4OpuM4fsWbQIGKv4A0ZWer6qRYCW0EA4HbLdYOf2fC38HJI8ANVtO5qAP2wBqKzNwBto7PzvjnvkeW80HIhB__jHLtlqMi5Rl_SBbCwXK_0RKNcy_7QeYX8AKC8q4w
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswEB2kKVLk0j2o0yU89NACkWRJlEwdCzeunTqBEThBeiIokUTV2LLhJWj6Vf3EzlhmNvSUiyCA1ELpSXwjvXkD8DFqJtoU3Hg21srjItOe0pZEjmEeam543KTk5KPjtHvKD8-T8w0QLhdmJdov8tKvRmO_Kn-utJXTcRE4nVgwOGqHzUxEWTDVNngEjxPyTHdx-vr_AQY53PmEY_v5WtmFL-Pg12XptyKf-zGG-x4uYsrYE9uwlSU4_5Pn6u0ZyrkG_4-B3hdS3pqZOs_ghxtTLUi58JeL3C_-3LN7fMign8PTNV1lX-oeL2DDVC9hqy5gefUK_p5MFuqynC3nLApSdkZro_LCsIHbJ3PuvFQTlPVoAJWaq9HoitEnYNam-rwzxYaT32W1zw7mBKKSBNgMIVqyLs4VXp9sgE3dh33qDz_vM1Vp1h96J0gdvzGqP1LgQWvPCUQao6wZdnNybVcy5jWcdg6G7a63rgHhFTwVC8-KjOxvkHcZm2sjcqTZXKQWkWcE2adZofOisBYvD0cqm9ik1bQ8iyj21nES78BmNanMG2BZGNm4hZQy1zkPVSowgBaqFSOnNFGkeQOa7r7LaW31IVchUiTk4VlPtiLJJYGGFrEk0DRg1-FDqvlYIrZuujVgzyFG4jNLP2JUZSbLuQzJGhqJZwN2avxcH28NwQakd4B13U5m4HdbEC4rU_AaHrsP3XAPngy-dmS_d_z9LWzXiZckT3oHm4vZ0rxH5rXIP6wesn99wS1j
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rotavirus+2%2F6+viruslike+particles+administered+intranasally+with+cholera+toxin%2C+Escherichia+coli+heat-labile+toxin+%28LT%29%2C+and+LT-R192G+induce+protection+from+rotavirus+challenge&rft.jtitle=Journal+of+virology&rft.au=O%27Neal%2C+C+M&rft.au=Clements%2C+J+D&rft.au=Estes%2C+M+K&rft.au=Conner%2C+M+E&rft.date=1998-04-01&rft.issn=0022-538X&rft.volume=72&rft.issue=4&rft.spage=3390&rft_id=info:doi/10.1128%2Fjvi.72.4.3390-3393.1998&rft_id=info%3Apmid%2F9525668&rft.externalDocID=9525668
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon